



Photo by Illumina

## The path to precision medicine in Indonesia

*The Illumina Genomics Summit highlighted the role of strategic collaborations to improve health outcomes in the country*

THE RECENT ILLUMINA GENOMICS SUMMIT in Jakarta, Indonesia, cohosted by Pandu Biosains, saw encouraging participation from Indonesia’s Ministry of Health, public health leaders, and over 300 genomics experts, clinicians, researchers, industry professionals, and academics. They shared insights about genomic research and the path to precision medicine.

Indri Rooslamiati, director of the Ministry of Health’s Center for Biomedical and Genomic Health and Clinical Research Center, said that the summit “is an important platform to demonstrate how cutting-edge technologies and strategic partnerships can address national health priorities.” She continued, “By collaborating with Illumina and Pandu Biosains, we are taking critical steps toward improving genomic surveillance, upgrading the country’s sequencing infrastructure, and moving closer to integrating genomics into Indonesia’s health care system.”

Indonesia faces persistent health care challenges due to chronic diseases such as diabetes and cardiovascular conditions, which affect over 25 million people in the country.<sup>1</sup> Personalized medicine is a critical component of the future of health care, and the event underscored

how advances in next-generation sequencing (NGS) technologies are making precision diagnostics and treatments more accessible in Indonesia.

“Our long-term partnership with the Ministry of Health supporting the national Biomedical and Genome Science Initiative underscores our commitment to driving innovation and enhancing the health and well-being of Indonesians,” a spokesperson for Illumina said. “We are also excited to collaborate with the private sector and research institutions to help shape the genomic landscape in Indonesia, including solutions for agriculture, microbiology, and other non-human genotyping. The launch of the MiSeq i100 today marks a key milestone in this effort.”

The MiSeq i100 Series<sup>2</sup> is designed to empower customers to unlock powerful insights, and it’s simple to understand and use, even for those with limited sequencing expertise. Its enhanced speed, simplicity, scalability, and quality—and its intuitive user experience—set a new standard for benchtop sequencing.

“Over the next five years, Indonesia’s genomics market is set for significant growth, fueled by government

1. [kenresearch.com/industry-reports/indonesia-genomics-market](https://www.kenresearch.com/industry-reports/indonesia-genomics-market)

2. [illumina.com/systems/sequencing-platforms/miseq-i100.html](https://www.illumina.com/systems/sequencing-platforms/miseq-i100.html)

**For Research Use Only. Not for use in diagnostic procedures.**

© 2025 Illumina, Inc. All rights reserved. All trademarks are the property of Illumina, Inc. or their respective owners. For specific trademark information, see [www.illumina.com/company/legal.html](https://www.illumina.com/company/legal.html).

support and advancements in sequencing technologies,” said Ria Putri Rahmadani, president and director of Pandu Biosains. “With Illumina, we are dedicated to fostering innovation and creating a future where science, technology, and collaboration drive meaningful impact for Indonesia and beyond.”

As personalized medicine and AI-enhanced health

care gain momentum, the future of genomics in Indonesia looks promising. Illumina and the Ministry of Health share a vision to make genomic solutions more accessible and impactful. Together, they are committed to empowering local researchers and clinicians to make life-changing discoveries that will improve health outcomes for Indonesians. ♦